A very high tumor mutational burden (TMB) is associated with improved efficacy of PD-(L)1 inhibition across different PD-L1 expression subgroups and a distinct immunophenotype in NSCLC Meeting Abstract

  

Authors:	Ricciuti, B.; Arbour, K. C.; Mahadevan, N. R.; Alessi, J. V.; Lindsay, J.; Umeton, R.; Sinha, R.; Hoojghan, A.; Vokes, N.; Recondo, G.; Lamberti, G.; Polio, A.; Rizvi, H.; Leonardi, G.; Plodkowski, A. J.; Felt, K.; Sharma, B.; Tolstorukov, M. Y.; Janne, P. A.; Van Allen, E. M.; Sholl, L. M.; Rodig, S. J.; Hellmann, M. D.; Awad, M. M.
Abstract Title:	A very high tumor mutational burden (TMB) is associated with improved efficacy of PD-(L)1 inhibition across different PD-L1 expression subgroups and a distinct immunophenotype in NSCLC
Meeting Title:	112th Annual Meeting of the American Association for Cancer Research (AACR)
Journal Title:	Cancer Research
Volume:	81
Issue:	13 Suppl.
Meeting Dates:	2021 Apr 10-15/May 17-21
Meeting Location:	Philadelphia, PA
ISSN:	0008-5472
Publisher:	American Association for Cancer Research
Date Published:	2021-07-01
Language:	English
ACCESSION:	WOS:000680263504344
PROVIDER:	wos
DOI:	10.1158/1538-7445.AM2021-490
Notes:	Meeting Abstract: 490 -- Due to Covid 19 pandemic, the conference was held virtually -- Source: Wos

https://synapse.mskcc.org/synapse/works/has_related_data_chk/186806